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Saudi ArabiaAbstract Background: Patients with mental disorders, such as depression and anxiety, who seek
medical care in private psychiatric clinics in Riyadh, Saudi Arabia, have recently expressed concerns
to doctors about difficulty in filling psychotropic medications, such as Amitriptyline and Aripipra-
zole, at retail community pharmacies. Objectives: The aim of this study was to investigate whether
there is a shortage of some commonly prescribed psychotropic medications in retail community
pharmacies in Saudi Arabia, and if so, to explore the possible reasons behind the shortage of these
medications. Methods: The availability of 28 commonly prescribed psychotropic medications was
checked in multiple retail community pharmacies in 4 different regions of Saudi Arabia. Further,
potential reasons behind the shortage of some psychotropic medications in retail community phar-
macies were also explored. Results: Amitriptyline, Amoxapine, Aripiprazole, Bupropion, Bus-
pirone, Duloxetine, Haloperidol, Hydroxyzine, Lithium, Prochlorperazine, Procyclidine,
Promethazine, Thioridazine, Trazodone, and Trifluoperazine were unavailable in over half of the
248 community pharmacies surveyed. Four possible reasons behind the shortage of these medica-
tions were reported by 31 pharmacists working in different retail community pharmacies’ purchas-
ing departments, with a majority (58.06%) reporting the primary reason for a shortage of these77480.
s. Saudi
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Pharmaceutical Journal (2016), http://dx.doimedications that they are slow-moving items with low profit margins. Conclusions: The findings of
this study should expedite the reform process in both the Ministry of Health and the Saudi Food
and Drug Authority (SFDA) to publish and enforce an essential list of medications for retail com-
munity pharmacies, which should include the most commonly prescribed psychotropic medications.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Until the preliminary results of the Saudi National Mental
Survey are available, there are currently no accurate estimates
of the prevalence of mental illness, such as depression and
schizophrenia, in Saudi Arabia (Koenig et al., 2014). However,
based on the most recent data published by the World Health
Organization (WHO), the prevalence of mental illness is
approximately 25% in both developed and under-developed
nations (Mental health atlas, 2015). Moreover, some studies
suggest a higher prevalence of mental illness among women,
divorcees, widowed, and older adults in the Kingdom of Saudi
Arabia (Koenig et al., 2014; Al-Shammari and Al-Subaie,
1999; Abdel-Fattah and Asal, 2006). In the last decade, the
divorce rate has tremendously increased in the kingdom reach-
ing up to 20% of all new marriages (AlMunajjed, 2010). Fur-
thermore, the kingdom is surrounded by countries rife with
armed conflicts and war, which puts the population at a
greater risk of mental illness (Dimitry, 2012).
The financial and emotional burden of mental illness is
enormous, on not only those who are ill and their loved ones,
but also employers, governments, and society as a whole
(Greenberg and Birnbaum, 2005; Insel, 2008; Kessler et al.,
2009). Therefore, several treatment approaches have been,
and are still used to manage these debilitating illnesses, such
as psychotherapy and pharmacotherapy (Pinquart et al.,
2006). Although some psychological interventions, such as
Cognitive Behavioral Therapy (CBT), have been shown to be
effective in the treatment of some mental disorders such as
depression (DeRubeis et al., 2008), pharmacotherapy is used
in the vast majority of mental illness cases and has also been
proven to be effective (Frank et al., 2005; Hieronymus et al.,
2016). As a result, the spending on psychotropic medications
has increased significantly over the last 3 decades (Frank
et al., 2005; Mark et al., 2005). For example, while the average
U.S. spending on drugs overall grew 11.5% in 2003, the spend-
ing on antipsychotics alone grew 22.1% in same year (Frank
et al., 2005). Furthermore, the demand on antidepressants in
the U.S. grew by 3.4% in 2015; however, it grew only 1%
for drugs overall in the same year (IMS Health, 2015).
In Saudi Arabia, there is a universal healthcare system
where citizens can visit any primary care clinic or hospital that
belongs to the Ministry of Health without incurring any
charges (Almalki et al., 2011). Furthermore, prescribed medi-
cations for citizens are fully covered and dispensed within
the same health facility in which the patient sought medical
care (Almalki et al., 2011). However, many patients, especially
in Muslim communities, would rather visit private facilities for
their mental illness, due to the associated social stigma (Ciftci
et al., 2013; Alamri, 2016). In addition, almost a third of the
Saudi population are non-citizens, who do not have access to
the free health care that the citizens enjoy, and have to either.S. et al., Shortage of psychotropic med
.org/10.1016/j.jsps.2016.10.013buy their own health insurance, or use healthcare coverage
provided by employers (Almalki et al., 2011; De Bel-Air, 2014).
The availability of psychotropic medications, such as
antidepressant and antipsychotics, is essential for the initiation
and continuity of patient care. Drug shortages can lead to
many unexpected consequences, such as a delay of therapy,
switching to another medication, and increased patient moni-
toring (McLaughlin et al., 2013). Recently, there have been
several complaints expressed by some psychiatrists who prac-
tice in private clinics in Riyadh, Saudi Arabia. Specifically,
that their patients are finding it difficult to fill prescriptions
for non-controlled prescription drugs at retail community
pharmacies. Thus, the current study investigated the authentic-
ity of these complaints through determination of the availabil-
ity of some highly demanded and prescribed psychotropic
medications (e.g., selective serotonin reuptake inhibitors
(SSRIs), serotonin-norepinephrine reuptake inhibitors
(SNRIs), typical and atypical antipsychotics, and lithium) that
have been reported to be in short supply in retail community
pharmacies by some psychiatrists.2. Methods
2.1. Study design and sampling plan
A cross-sectional study design was used to explore the preva-
lence of psychotropic drug shortage at retail community phar-
macies, primarily in Riyadh, Saudi Arabia. A convenience
sample of 300 community pharmacies was chosen. This
method was used due to time and resource limitations; how-
ever, community pharmacies from different locations as well
as from different regions were included to make the sample
as representative as possible. This study was approved by the
Institutional Review Board (IRB) office of the College of Phar-
macy at King Saud University.
2.2. Data collection
Psychiatrists in private clinics were contacted and asked to
provide a list of the medications that were reported to be in
short supply by their patients. This list included 28 medica-
tions, which were as follows: Amitriptyline, Amoxapine, Arip-
iprazole, Bupropion hydrochloride (HCl), Buspirone HCl,
Carbamazepine, Citalopram, Duloxetine HCl, Escitalopram,
Fluoxetine, Haloperidol, Hydroxyzine HCl, Lamotrigine,
Lithium, Olanzapine, Paroxetine, Prochlorperazine, Procy-
clidine, Promethazine, Quetiapine, Risperidone, Sertraline,
Thioridazine, Topiramate, Trazodone, Trifluoperazine, Val-
proic acid, and Venlafaxine. Some of these medications have
been listed by the World Health Organization (WHO) as essen-
tial medicines for mental disorders in primary health careications in community pharmacies in Saudi Arabia: Causes and solutions. Saudi
Psychotropic drug shortages in retail pharmacies 3(World Health Organization, 2009). Four pharmacy interns
visited 240 retail community pharmacies in the city Riyadh
(central region) and contacted by phone 60 community phar-
macies in the cities of Dammam and Khobar (Eastern region),
Jeddah and Madinah (Western region), and Buraydah and
Hail (Northern region). The pharmacy interns asked the phar-
macists whether they carry any of the above-mentioned medi-
cations in their pharmacies. An electronic data collection sheet
using Google Forms was created to facilitate the data collec-
tion process. Furthermore, the pharmaceutical care depart-
ment and the office responsible for the regulation and
oversight of private sector in the Ministry of Health were con-
tacted to obtain the mandatory list of psychotropic medica-
tions, if any, that must be available in any registered retail
community pharmacy. For this study, psychotropic medica-
tion was regarded to be in short supply if >50% of the visited
or contacted retail community pharmacies did not carry the
medication. Moreover, the office responsible for handling drug
shortage reports at the Saudi Food and Drug Authority
(SFDA) was contacted to determine whether any drug short-
age reports concerning any of the above-mentioned psy-
chotropic medications were received. In addition, the drug
purchasing departments in 31 retail community pharmacies
were contacted to explore potential reasons behind some psy-
chotropic medications shortage at retail community pharma-
cies in Saudi Arabia.
2.3. Statistical analysis
The availability of the above-mentioned psychotropic medica-
tions was compared between chain and independent commu-
nity pharmacies, as well as between the community
pharmacies in the different regions, using chi-square tests
and Fisher’s exact tests, as appropriate. Statistical significance
was determined at an a of 0.05. All statistical analyses were
performed using SAS version 9.2 (SAS Institute, Inc., Cary,
NC, USA).
3. Results
Among the 300 retail community pharmacies that were visited
or contacted, 248 pharmacies agreed to participate in this sur-
vey. From the 28 psychotropic medications that were checked,
15 medications were available in <50% of the surveyed retail
community pharmacies (Table 1). In addition, the chain com-
munity pharmacies were more likely to have these medications
available than the independent community pharmacies
(Table 1). Some medications were only available in a few of
the community pharmacies in the central region, such as
Thioridazine, or in 2 of the 4 surveyed regions, such as
Amitriptyline and Trazodone (Table 2).
The SFDA was contacted to determine whether any of
these psychotropic medications were recently reported to be
in short supply, or whether they were contacted regarding
the unavailability of any of these medications in community
pharmacies. According to the SFDA, no reports were received
from either pharmacy owners or patients. Although there are
regulations governing the registration and licensing of retail
community pharmacies in Saudi Arabia, these regulations do
not recommend, or enforce, any list of prescription drugs that
should be available in retail community pharmacies. This wasPlease cite this article in press as: Al-Ruthia, Y.S. et al., Shortage of psychotropic med
Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.10.013confirmed through contact of the pharmaceutical care depart-
ment and the office responsible for the regulation and over-
sight of private sector in the Ministry of Health. Moreover,
the 31 pharmacists from the purchasing departments of differ-
ent retail community pharmacies who were contacted by
phone reported 4 reasons behind the shortage of some psy-
chotropic medications in retail community pharmacies in
Saudi Arabia. These reasons were as follows: (1) psychotropic
medications are slow moving items with low profit margin; (2)
governmental regulations for purchasing and dispensing psy-
chotropic medications are very strict, regardless of controlled
status (e.g. narcotics and central nervous system stimulants);
(3) procuring psychotropic medications from licensed pharma-
ceutical agents or wholesalers is difficult; and (4) overall high
acquisition cost of psychotropic medications (Fig. 1).4. Discussion
The impact of mental illness on the patients, healthcare sys-
tems, and societies overall is enormous, if left untreated
(Insel, 2008; Kessler et al., 2009; Mark et al., 2005). Therefore,
the availability of psychotropic medications is essential for the
continuity of patient care (McLaughlin et al., 2013). Although
some studies have examined the possible causes of drug short-
ages in general in hospital pharmacies in Saudi Arabia, and
found that poor inventory management was mainly behind
these shortages (Alshehri and Alshammari, 2016; AL-Aqeel
et al., 2010), no study so far has examined the shortages of psy-
chotropic medications either in hospital or in retail community
pharmacies. This study explored the prevalence of shortages of
some psychotropic medications, either brand or generic, in
retail community pharmacies, primarily in the capital of Saudi
Arabia (Riyadh), as well as in 3 other regions. Some psy-
chotropic medications, such as Amitriptyline, Haloperidol,
and Lithium, which are categorized by the WHO as essential
medicines for the treatment of mental disorders in primary
healthcare settings, were not available in a majority of the
community pharmacies surveyed (World Health
Organization, 2009). Many Saudi citizens prefer to seek medi-
cal care for their mental illness in private hospitals or clinics,
due to the strongly attached social stigma of mental illness in
Middle Eastern societies (Alamri, 2016). Furthermore, Saudi
Arabia hosts approximately 10 million legal residents who
are non-citizens (De Bel-Air, 2014). These residents do not
have access to the free health care provided to citizens by the
Ministry of Health affiliated hospitals, and most seek medical
care in private health facilities (Almalki et al., 2011). This seg-
ment of the population with mental illness, who avoid visiting
governmental health facilities either due to lack of access or
due to the social stigma associated with their mental illness,
are the ones primarily affected by the shortage of these medi-
cations in retail community pharmacies.
Although some studies have suggested higher customer loy-
alty to small independent pharmacies (Perepelkin and Di
Zhang, 2011), this may not hold true all the time
(Mohammadzadeh et al., 2014). For example, customer loyalty
to chain community pharmacies was higher than independent
pharmacies in Iran (Mohammadzadeh et al., 2014). Since the
availability of medications is considered one of the most
influential variables that impact customer loyalty (Bahari
and Ling, 2010) this may explain the higher percentage ofications in community pharmacies in Saudi Arabia: Causes and solutions. Saudi
Table 1 The availability of psychotropic medications in chain and independent community pharmacies.
Medication name Type of pharmacy P value Total (n = 248)
Independent (n = 62) Chain (n = 186)
Amitriptyline 9(14.52%) 30(16.13%) 0.842 39(15.73%)
Amoxapine 2(3.23%) 4(2.15%) 0.641 6(2.42%)
Aripiprazole 13(20.97%) 75(40.32%) 0.005* 88(35.48%)
Bupropion 8(12.90%) 43(23.12%) 0.102 51(20.56%)
Buspirone 8(12.90%) 38(20.43%) 0.257 46(18.55%)
Carbamazepine 36(58.06%) 120(64.52%) 0.367 156(62.90%)
Citalopram 54(87.10%) 172(92.47%) 0.203 226(91.13%)
Duloxetine 21(33.87%) 93(50.00%) 0.028* 114(45.97%)
Escitalopram 50(80.65%) 172(92.47%) 0.014 222(89.52%)
Fluoxetine 47(75.81%) 166(89.25%) 0.011 213(85.89%)
Haloperidol 2(3.23%) 20(10.75%) 0.076 22(8.87%)
Hydroxyzine 6(9.68%) 11(5.91%) 0.382 17(6.85%)
Lamotrigine 28(45.16%) 132(70.97%) 0.001* 160(64.52%)
Lithium 0(0.00%) 0(0.00%) 1.00 0(0.00%)
Olanzapine 30(48.39%) 135(72.58%) 0.001* 165(66.53%)
Paroxetine 50(80.65%) 164(88.17%) 0.135 214(86.29%)
Prochlorperazine 3(4.84%) 5(2.69%) 0.416 8(3.23%)
Procyclidine 3(4.84%) 7(3.76%) 0.714 10(4.03%)
Promethazine 13(20.97%) 49(26.34%) 0.397 62(25.00%)
Quetiapine 29(46.77%) 135(72.58%) 0.001* 164(66.13%)
Risperidone 42(67.74%) 155(83.33%) 0.008* 197(79.44%)
Sertraline 27(43.55%) 134(72.04%) <0.001* 161(64.92%)
Thioridazine 5(8.06%) 6(3.23%) 0.1488 11(4.44%)
Topiramate 18(29.03%) 109(58.60%) <0.001* 127(51.21%)
Trazodone 7(11.29%) 10(5.38%) 0.143 17(6.85%)
Trifluoperazine 1(1.61%) 9(4.84%) 0.458 10(4.03%)
Valproic acid 36(58.06%) 137(73.66%) 0.020* 173(69.76%)
Venlafaxine 32(51.61%) 152(81.72%) <0.001* 184(74.19%)
* P< 0.05.
4 Y.S. Al-Ruthia et al.chain community pharmacies that carry some of the surveyed
psychotropic medications in comparison with independent
pharmacies. All of the previously mentioned psychotropic
medications, with the exception of Lithium, were available in
variable percentages in the surveyed community pharmacies
in the central region; however, some psychotropic medications
were only available in the central region. This could be
explained by the small number of pharmacies that were sur-
veyed outside the central region.
The absence of any reports concerning shortages of the sur-
veyed psychotropic medications to the SFDA suggests that the
reasons behind the unavailability of some psychotropic medi-
cations in retail community pharmacies may lie within the
community pharmacies themselves. Therefore, the purchasing
departments in 31 different retail pharmacies were contacted
to explore the potential reasons behind these shortages. Not
all pharmacists who were interviewed by the phone reported
the same reason behind this shortage in their community phar-
macies. For example, 4 pharmacists (12.9%) reported that the
cost of purchasing and storing these medications is expensive,
despite the fact that these medications are uncontrolled drugs.
On the other hand, 2 pharmacists (6.45%) reported that pur-
chasing these medications from their licensed pharmaceutical
agents, and receiving them within a reasonable amount of
time, is difficult due to the very limited quantity that those
agents have on hand. Furthermore, 7 pharmacists (22.58%)
cited as a reason the strict regulations stipulated by the Min-
istry of Health that govern the purchase, storage, and sale ofPlease cite this article in press as: Al-Ruthia, Y.S. et al., Shortage of psychotropic med
Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.10.013psychotropic medications, regardless of controlled status, such
as narcotics. Some pharmacists expressed dissatisfaction in the
fact that the Ministry of Health inspectors who visit their sites
do not differentiate between uncontrolled drugs, such as
antipsychotics, and the controlled drugs, such as the narcotics,
and file a report against any pharmacy that does not specify
the place where these medications should be kept and stored.
However, the majority of the pharmacists interviewed
(58.06%) reported that the main reason behind not having
these medications in their pharmacies was that these medica-
tions are slow moving items with low profit margins.
The findings of this study suggest that there are multiple
areas for improvement in terms of having sound and effective
drug policies in Saudi Arabia. Currently, the SFDA is the gov-
ernmental entity responsible for the registration of medications
and handling of medication shortage reports. In addition, the
Ministry of Health is responsible for the licensing of any retail
community pharmacy, as well as setting and enforcing regula-
tions that govern the work within these vital settings. In some
countries, such as Ethiopia, the governmental authority
responsible for food, medicine, and healthcare administration
and control, alongside with the Ministry of Health, and in col-
laboration with the WHO, put together a list of essential med-
ications for community pharmacies, that includes a list of
essential psychotropic medications, to ensure the continuity
of patient care (List of Medicines for Community Pharmacy,
2012). Unfortunately, no list of psychotropic or non-
psychotropic medications for community pharmacies existsications in community pharmacies in Saudi Arabia: Causes and solutions. Saudi
Table 2 The availability of psychotropic medications in community pharmacies in different regions.
Medication name Region P value Total (n = 248)
Central (n = 227) Western (n = 10) Eastern (n = 5) Northern (n = 6)
Amitriptyline 37(16.30%) 0(0.00%) 2(40.00%) 0(0.00%) 0.180 39(15.73%)
Amoxapine 5(2.20%) 0(0.00%) 1(20.00%) 0(0.00%) 0.162 6(2.42%)
Aripiprazole 75(33.04%) 8(80.00%) 2(40.00%) 3(50.00%) 0.014* 88(35.48%)
Bupropion 43(18.94%) 6(60.00%) 2(40.00%) 0(0.00%) 0.007* 51(20.56%)
Buspirone 43(18.94%) 1(10.00%) 2(40.00%) 0(0.00%) 0.362 46(18.55%)
Carbamazepine 143(63.00%) 7(70.00%) 2(40.00%) 4(66.67%) 0.708 156(62.90%)
Citalopram 206(90.75%) 9(90.00%) 5(100.00%) 6(100.00%) 1.000 226(91.13%)
Duloxetine 100(44.05%) 9(90.00%) 3(60.00%) 2(33.33%) 0.017* 114(45.97%)
Escitalopram 201(88.55%) 10(100.00%) 5(100.00%) 6(100.00%) 0.886 222(89.52%)
Fluoxetine 193(85.02%) 10(100.00%) 5(100.00%) 5(83.33%) 0.568 213(85.89%)
Haloperidol 21(9.25%) 0(0.00%) 1(20.00%) 0(0.00%) 0.492 22(8.87%)
Hydroxyzine 15(6.61%) 1(10.00%) 1(20.00%) 0(0.00%) 0.356 17(6.85%)
Lamotrigine 145(63.88%) 8(80.00%) 3(60.00%) 4(66.67%) 0.811 160(64.52%)
Lithium 0(0.00%) 0(0.00%) 0(0.00%) 0(0.00%) 1.000 0(0.00%)
Olanzapine 152(66.96%) 9(90.00%) 2(40.00%) 2(33.33%) 0.057 165(66.53%)
Paroxetine 193(85.02%) 10(100.00%) 5(100.00%) 6(100.00%) 0.518 214(86.29%)
Prochlorperazine 8(3.52%) 0(0.00%) 0(0.00%) 0(0.00%) 1.000 8(3.23%)
Procyclidine 9(3.96%) 1(10.00%) 0(0.00%) 0(0.00%) 0.594 10(4.03%)
Promethazine 59(25.99%) 0(0.00%) 2(40.00%) 1(16.67%) 0.177 62(25.00%)
Quetiapine 150(66.08%) 8(80.00%) 4(80.00%) 2(33.33%) 0.264 164(66.13%)
Risperidone 178(78.41%) 109(100.00%) 3(60.00%) 6(100.00%) 0.129 197(79.44%)
Sertraline 146(64.32%) 9(90.00%) 5(100.00%) 1(16.67%) 0.007* 161(64.92%)
Thioridazine 11(4.44%) 0(0.00%) 0(0.00%) 0(0.00%) 1.000 11(4.44%)
Topiramate 113(49.78%) 8(80.00%) 4(80.00%) 2(33.33%) 0.124 127(51.21%)
Trazodone 15(6.61%) 0(0.00%) 2(40.00%) 0(0.00%) 0.091 17(6.85%)
Trifluoperazine 10(4.41%) 0(0.00%) 0(0.00%) 0(0.00%) 1.000 10(4.03%)
Valproic acid 157(69.17%) 7(70.00%) 4(80.00%) 5(83.33%) 0.967 173(69.76%)
Venlafaxine 168(74.01%) 9(90.00%) 4(80.00%) 3(50.00%) 0.372 184(74.19%)
* P< 0.05.
18, 58%
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2, 6%
7, 23%
Slow moving items
High drug acquisition 
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the pharmaceutical 
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Strict regulations
Figure 1 Possible reasons for shortage of some psychotropic medications from the perspective of community pharmacists (n = 31).
Psychotropic drug shortages in retail pharmacies 5in Saudi Arabia, let alone enforcement of such a list. Presenta-
tion and enforcement of a list of essential medications for retail
community pharmacies are needed to create a balance between
business and patient care. Closer cooperation and coordina-
tion are required in the future between these 2 governmental
entities to ensure patient safety and continuity of care.Please cite this article in press as: Al-Ruthia, Y.S. et al., Shortage of psychotropic med
Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.10.0135. Limitations
This study has several limitations. First, the data were not col-
lected in the same manner across all pharmacies. For example,
retail community pharmacies in the central region were visited
in-person, which was in contrast to pharmacies in the otherications in community pharmacies in Saudi Arabia: Causes and solutions. Saudi
6 Y.S. Al-Ruthia et al.regions. Furthermore, the generalizability of the findings is
limited due to the underrepresentation of the retail community
pharmacies outside the central region. These limitations were
mainly due to the limited funding that this study received.
6. Conclusions
The availability of essential medications is vital for patient
care. In Saudi Arabia, the loose regulations that govern the
licensing and work of retail community pharmacies jeopardize
the continuity of patient care, especially for patients with men-
tal illness. Such loose regulation has resulted in a shortage of
certain essential medications, such as Lithium, from retail
community pharmacies. Future research should examine the
impact of this shortage on the lives of patients and their fam-
ilies. In addition, future research should explore other poten-
tial reasons behind the drug shortages, solutions to address
these shortages, and the impact of any future drug policy
reform to address this serious issue.
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